Oklahoma Specialized Center of Research in SLE

描述（由申请人提供）：俄克拉何马州医学研究基金会提议建立系统性红斑狼疮专门研究中心（SCOR），该中心将专注于了解自身抗体在SLE中的作用。该中心的总体目标是将临床风湿病研究与整个校园的基础科学研究人员结合起来，从而加强该州的基础科学和以患者为导向的研究。Morris Reichlin博士是主任，他为这个新的综合项目带来了风湿病研究活动的杰出职业生涯。简而言之，这个SCOR有五名关键研究员，五名合作研究员（州内），五名合作研究员（州外），九名额外的关节炎研究员，十四名基础科学研究员，一名数据和分析核心主任，咨询委员会和一大批兼职教师，博士后研究员，临床研究员，医学博士研究生和研究生。

DESCRIPTION (provided by applicant): The Oklahoma Medical Research Foundation proposes a Specialized Center of Research (SCOR) in systemic lupus erythematosus which will focus on understanding the roles of autoantibodies in SLE. The overarching goal of this center will be to integrate clinical rheumatic disease research with basic science investigators from throughout campus thereby strengthening basic science and patient oriented research in this state. Dr. Morris Reichlin is the Director, and he brings a distinguished career's worth of rheumatic disease research activities to this new integrated program. Briefly, this SCOR has five key investigators, five collaborating investigators (in-state), five collaborating investigators (out-of-state), nine additional arthritis investigators, fourteen basic science investigators, a Data and Analysis Core Director, Advisory Committee and a host of adjunct faculty, post-doctoral fellows, clinical fellows, MD-PhD students and graduate students. The key projects for this proposal include various approaches to understand how autoimmune responses start in SLE and how autoantibodies could lead to pathogenesis. The major projects in this SCOR will focus on understanding the development of autoantibodies with regards to symptom and SLE disease onset, exploring the role of autoantibodies in the development of dyslipidemias and accelerated cardiac disease, evaluating the basic role of B cell tolerance in the accrual of lupus autoantibodies, identifying potential etiologic triggers of these aberrant autoimmune responses and assessing the genetic predisposition to a severe serological and clinical SLE phenotype. A Data and Analysis Core and Administrative Core will support each of these individual projects. The primary Oklahoma SLE SCOR objectives are fourfold. First, this SCOR will strengthen research through integration of basic and clinical science in finding key etiological factors for SLE by supporting the above mentioned research projects. Second, biostatistical/research design issues will be incorporated into all ongoing rheumatic disease research in order to raise the current level of research activity. Third, key unique patient resources will be shared by several of the projects. Finally, this SCOR will provide a multidisciplinary structure and resources to strengthen current clinical rheumatic disease research through the influence of strong basic scientists involved in cardiovascular biology, lupus genetics, inflammation, coagulation, molecular biology, immunobiology, immunogenetics, clinical pharmacology and protein studies.